Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-up of HLH patients treated with NI-0501
2012-005753-23Phase 2Completed
- Sponsor
- Lightchain Bioscience
- Start
- Apr 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of emapalumab in haemophagocytic lymphohistiocytosis (HLH), sponsored by Lightchain Bioscience. Started Apr 2013; status: completed.
02
Drugs
emapalumab
03
Conditions
haemophagocytic lymphohistiocytosis (HLH)
Beyond the preview
Go deeper on 2012-005753-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-005753-23.